Event-Free Survival at 24 Months Is a Robust End Point for Disease-Related Outcome in Diffuse Large B-Cell Lymphoma Treated With Immunochemotherapy

PURPOSE: Studies of diffuse large B-cell lymphoma (DLBCL) are typically evaluated by using a time-to-event approach with relapse, re-treatment, and death commonly used as the events. We evaluated the timing and type of events in newly diagnosed DLBCL and compared patient outcome with reference popul...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Maurer, Matthew J., Ghesquières, Hervé, Jais, Jean-Philippe, Witzig, Thomas E., Haioun, Corinne, Thompson, Carrie A., Delarue, Richard, Micallef, Ivana N., Peyrade, Frédéric, Macon, William R., Jo Molina, Thierry, Ketterer, Nicolas, Syrbu, Sergei I., Fitoussi, Olivier, Kurtin, Paul J., Allmer, Cristine, Nicolas-Virelizier, Emmanuelle, Slager, Susan L., Habermann, Thomas M., Link, Brian K., Salles, Gilles, Tilly, Hervé, Cerhan, James R.
Formato: Artigo
Idioma:Inglês
Publicado em: American Society of Clinical Oncology 2014
Assuntos:
ORIGINAL REPORTS
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC3965261/
https://ncbi.nlm.nih.gov/pubmed/24550425
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2013.51.5866
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados